Drug Search Results
More Filters [+]

Arbekacin

Alternative Names: arbekacin, npc-14
Latest Update: 2024-02-07
Latest Update Note: PubMed Publication

Product Description

Arbekacin is a broad-spectrum aminoglycoside used to treat methicillin-resistant Staphylococcus aureus (MRSA). Arbekacin has antibacterial activities against high-level gentamicin-resistant Enterococci, multidrug-resistant Pseudomonas aeruginosa, and Acinetobacter baumannii et al. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835429/)

Mechanisms of Action: 30S Ribosomal Subunit Binder

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous,Oral,Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Japan | Korea

Approved Indications: None

Known Adverse Events: None

Company: Meiji Seika Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Arbekacin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Muscular Dystrophy, Duchenne

Phase 1: Healthy Volunteers|Pneumonia, Bacterial

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ME1100-CL-103

P1

Completed

Pneumonia, Bacterial

2017-03-22

NORTH POLE DMD

P2

Unknown status

Muscular Dystrophy, Duchenne

2015-10-01

ME1100-CL-102

P1

Completed

Healthy Volunteers

2013-12-01

ME1100-CL-101

P1

Completed

Healthy Volunteers

2013-12-01

Recent News Events